New therapeutic strategies for malignant pleural mesothelioma
- PMID: 27431778
- DOI: 10.1016/j.bcp.2016.07.012
New therapeutic strategies for malignant pleural mesothelioma
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. Therapeutic actions are limited due to the late stage at which most patients are diagnosed and the intrinsic chemo-resistance of the tumor. The recommended systemic therapy for MPM is cisplatin/pemetrexed regimen with a mean overall survival of about 12months and a median progression free survival of less than 6months. Considering that the incidence of this tumor is expected to increase in the next decade and that its prognosis is poor, novel therapeutic approaches are urgently needed. For some tumors, such as lung cancer and breast cancer, druggable oncogenic alterations have been identified and targeted therapy is an important option for these patients. For MPM, clinical guidelines do not recommend biological targeted therapy, mainly because of poor target definition or inappropriate trial design. Further studies are required for a full comprehension of the molecular pathogenesis of MPM and for the development of new target agents. This review updates pre-clinical and clinical data on the efficacy of targeted therapy and immune checkpoint inhibition in the treatment of mesothelioma. Finally, future perspectives in this deadly disease are also discussed.
Keywords: Immunotherapy; MPM; Target therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Is there a role for immunotherapy in malignant pleural mesothelioma?Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x. Med Oncol. 2018. PMID: 29845408 Review.
-
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.JCI Insight. 2018 Apr 5;3(7):e98575. doi: 10.1172/jci.insight.98575. eCollection 2018 Apr 5. JCI Insight. 2018. PMID: 29618661 Free PMC article.
-
Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.Eur J Med Chem. 2017 Dec 15;142:266-270. doi: 10.1016/j.ejmech.2017.07.063. Epub 2017 Aug 2. Eur J Med Chem. 2017. PMID: 28800871 Review.
-
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5. doi: 10.1080/14737140.2016.1191951. Epub 2016 May 30. Expert Rev Anticancer Ther. 2016. PMID: 27224058 No abstract available.
-
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.Am J Respir Cell Mol Biol. 2014 May;50(5):870-5. doi: 10.1165/rcmb.2013-0472TR. Am J Respir Cell Mol Biol. 2014. PMID: 24450537 Review.
Cited by
-
Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights.Open Respir Arch. 2024 Apr 5;6(3):100323. doi: 10.1016/j.opresp.2024.100323. eCollection 2024 Jul-Sep. Open Respir Arch. 2024. PMID: 38660145 Free PMC article. Review.
-
Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.Cancers (Basel). 2023 May 27;15(11):2940. doi: 10.3390/cancers15112940. Cancers (Basel). 2023. PMID: 37296902 Free PMC article. Review.
-
High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma.Biomed Res Int. 2023 Apr 24;2023:6575194. doi: 10.1155/2023/6575194. eCollection 2023. Biomed Res Int. 2023. PMID: 37139482 Free PMC article.
-
Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.Target Oncol. 2022 Jul;17(4):407-431. doi: 10.1007/s11523-022-00900-2. Epub 2022 Jul 30. Target Oncol. 2022. PMID: 35906513 Free PMC article. Review.
-
Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing.Mater Today Bio. 2022 Jul 12;16:100357. doi: 10.1016/j.mtbio.2022.100357. eCollection 2022 Dec. Mater Today Bio. 2022. PMID: 35880098 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical